Perifosine is an oral Akt inhibitor, currently evaluated in phase III clinical trials, shown to inhibit Akt and mitogen-activated protein kinase (MAPK) phosphorylation in prostate PC3 cells, multiple myeloma, HCC, glioma cells and renal carcinoma [50-54].
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}